CNC stock forecast, quote, news & analysis
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges... Show more
Centene Corporation (CNC) Stock Analysis: Turnaround Rally Faces Key Test with Q2 Earnings on Deck
Key Takeaways
- Centene Corporation (CNC) shares closed at $63.41 on July 24, 2026, down approximately 3.5% over the trailing 30-day period, reflecting a modest pullback from mid-July highs near $69.
- The stock has surged roughly 66% year-to-date in 2026, dramatically outperforming the S&P 500 and the broader managed-care sector, driven by a powerful earnings recovery and improving Medicaid margins.
- Q1 2026 adjusted EPS of $3.37 crushed Wall Street estimates by 58%, prompting management to raise full-year EPS guidance to above $3.40 and fueling a wave of analyst upgrades.
- Q2 2026 earnings are scheduled for release on July 28, with consensus estimates pointing to EPS of approximately $0.89 on revenue of $47.53 billion — a pivotal report that could define the next leg of the stock's trajectory.
- Analyst sentiment remains broadly constructive, with a consensus "Buy" rating and an average 12-month price target of roughly $65, though price targets from the most bullish firms extend as high as $80.
Current Market Snapshot
Centene shares have traded in a relatively contained range over the past month, consolidating between roughly $63 and $69 after a remarkable rally that carried the stock from a 52-week low of $25.08 to levels not seen in over a year. The stock has pulled back modestly from its mid-July peak, with the upcoming Q2 earnings report on July 28 serving as the next major catalyst. Broader managed-care peers such as UNH and ELV have posted more subdued year-to-date gains of approximately 30% and 21%, respectively, underscoring the magnitude of Centene's relative outperformance. Trading volumes have remained robust, and institutional ownership stands at approximately 93.6%, signaling deep professional interest in the name. With a forward P/E near 17-18x, the valuation has re-rated meaningfully from distressed levels but remains within historical norms for the managed-care industry.
Centene Corporation (CNC) Business Overview and Competitive Position
Centene Corporation is a Fortune 500 managed healthcare enterprise headquartered in St. Louis, Missouri, and is the largest pure-play Medicaid managed-care organization in the United States. The company operates through four segments — Medicaid, Medicare, Commercial, and Other — providing health insurance coverage and administrative services to more than 26 million members across all 50 states. Centene's core business revolves around government-sponsored healthcare programs: it administers Medicaid and Children's Health Insurance Program (CHIP) benefits, Medicare Advantage and Medicare Prescription Drug Plans (PDP), and Affordable Care Act Marketplace exchange plans. The company also contracts with federal and state agencies to deliver specialty care programs for vulnerable populations, including foster care, long-term services and supports, and dual-eligible Medicare-Medicaid plans. Centene's competitive strengths include its scale and deep expertise in navigating complex state-level Medicaid contracts, its diversified government-program portfolio, and a growing PDP membership base that expanded 11.6% year-over-year in the first quarter of 2026. With annual revenues in the range of $187-191 billion, Centene is one of the largest healthcare enterprises in the country, though its low-margin business model makes even modest improvements in medical cost ratios and operating efficiency highly impactful to earnings.
Recent Developments Driving CNC
The single most consequential recent event for Centene was its Q1 2026 earnings report released on April 28, which delivered adjusted EPS of $3.37 — 58% above the $2.23 consensus estimate — alongside revenue of $49.94 billion that topped forecasts by nearly $2.4 billion. The company's health benefits ratio (HBR) improved 20 basis points year-over-year to 87.3%, while premium revenues rose 5.2% to $43.9 billion, supported by stronger PDP enrollment and improving Medicaid reimbursement rates. Management raised its full-year 2026 premium and service revenue guidance to $171-$175 billion and lifted adjusted EPS guidance to above $3.40. The balance sheet also showed progress, with long-term debt declining 6% from year-end 2025 to $16.3 billion and net cash from operations surging to $4.4 billion in the quarter from $1.5 billion a year earlier.
This earnings beat triggered a cascade of analyst upgrades. Bank of America Securities upgraded CNC from Underperform to Buy, Cantor Fitzgerald raised its rating to Overweight, Deutsche Bank moved from Hold to Buy with an $80 price target, and Bernstein lifted its target to $68 while maintaining an Outperform rating. More recently, Cantor Fitzgerald raised its target further to $75, and Barclays maintained an Overweight rating with a $75 target. However, not all voices are uniformly bullish — Wells Fargo, Morgan Stanley, and TD Cowen have maintained Hold-equivalent ratings, while the consensus average price target of roughly $65 sits only modestly above the current share price, suggesting the rally has partially absorbed near-term upside. The upcoming Q2 2026 earnings release on July 28 is now the primary focus: analysts are forecasting EPS of $0.89, up sharply from the loss of $0.16 per share in the year-ago quarter, and investors will scrutinize Medicaid cost trends, Marketplace margin trajectory, and any updated forward guidance.
Trending AI Robots
For traders and investors seeking data-driven insights beyond traditional fundamental analysis, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots actively deployed across thousands of stocks and ETFs. Tickeron hosts hundreds of algorithmic trading bots, each designed with distinct strategies, time horizons, and risk-reward profiles, but only the most relevant and top-performing bots are featured in the Trending section. These bots analyze real-time market data, technical patterns, and momentum signals to identify actionable trading opportunities, providing a quantitative complement to conventional research. Whether you are looking for short-term swing trading signals or longer-duration trend-following strategies, exploring the Trending AI Robots page can help uncover algorithmically driven perspectives that may not be immediately visible through standard charting or fundamental analysis alone.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will shape Centene's trajectory through the remainder of 2026. First and foremost, the Q2 earnings report on July 28 will set the tone — investors will focus on whether the Medicaid margin stabilization narrative remains intact, whether Marketplace margins are tracking toward the targeted 3% level, and whether management provides any update to full-year guidance. Beyond earnings, state-level Medicaid rate negotiations and federal policy developments around the Affordable Care Act and Medicare remain critical variables, given that government-sponsored programs account for the vast majority of Centene's revenue. Medical cost trends and utilization patterns, particularly in higher-acuity Medicaid populations, will continue to be closely monitored. On the competitive front, Centene faces ongoing pressure from peers including UnitedHealth Group, Elevance Health, and Molina Healthcare in bidding for state Medicaid contracts. The Zacks Consensus Estimate for full-year 2026 EPS stands at $3.46, with further growth to $4.41 projected for 2027, implying continued operating leverage as the turnaround matures. Investors should also watch for any regulatory shifts stemming from the 2026 election cycle, which could influence the policy environment for Medicaid, Medicare, and Marketplace plans heading into 2027.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for CNC shows an upward move is likely
CNC's Aroon Indicator triggered a bullish signal on July 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 223 similar instances where the Aroon Indicator showed a similar pattern. In of the 223 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on CNC as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CNC just turned positive on August 07, 2026. Looking at past instances where CNC's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
CNC moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CNC crossed bullishly above the 50-day moving average on August 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.446) is normal, around the industry mean (3.737). P/E Ratio (9.063) is within average values for comparable stocks, (153.361). Projected Growth (PEG Ratio) (0.899) is also within normal values, averaging (1.234). CNC's Dividend Yield (0.000) is considerably lower than the industry average of (0.020). P/S Ratio (0.161) is also within normal values, averaging (0.579).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a multi-line healthcare enterprise
Industry ManagedHealthCare